As of 2025-07-08, the Intrinsic Value of Biohaven Pharmaceutical Holding Company Ltd (BHVN) is -43.51 USD. This BHVN valuation is based on the model Peter Lynch Fair Value. With the current market price of 13.79 USD, the upside of Biohaven Pharmaceutical Holding Company Ltd is -415.53%.
Based on its market price of 13.79 USD and our intrinsic valuation, Biohaven Pharmaceutical Holding Company Ltd (BHVN) is overvalued by 415.53%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -43.51 - -43.51 | -43.51 | -415.53% |
| P/E | (116.96) - (164.65) | (118.35) | -958.2% |
| DDM - Stable | (55.13) - (167.99) | (111.56) | -909.0% |
| DDM - Multi | (44.18) - (109.86) | (63.62) | -561.3% |
| Market Cap (mil) | 1,408.10 |
| Beta | 1.54 |
| Outstanding shares (mil) | 102.11 |
| Enterprise Value (mil) | 1,309.68 |
| Market risk premium | 4.60% |
| Cost of Equity | 11.86% |
| Cost of Debt | 5.00% |
| WACC | 8.42% |